Elena Jachetti
Researcher (non-academic)
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (27)
Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer that emerges as tumors become resistant to hormone therapies or, rarely, arises de novo in treatment-naïve patients. The urgent need for effective therapies against NEPC is hampered by the limited knowledge of the biology governing this lethal disease. Based on our prior observations in the transgenic adenocarcinoma of the mouse prostate (TRAMP) spontaneous prostate cancer model, in which the genetic depletion of either mast cells (MC) or the matricellular protein osteopontin (OPN) increases NEPC frequency, we tested the hypothesis that MCs can restrain NEPC through OPN production, using in vitro co-cultures between murine or human tumor cell lines and MCs, and in vivo experiments. We unveiled a role for the intracellular isoform of OPN, so far neglected compared with the secreted isoform. Mechanistically, we unraveled that the intracellular isoform of OPN promotes TNFα production in MCs via the TLR2/TLR4-MyD88 axis, specifically triggered by the encounter with NEPC cells. We found that MC-derived TNFα, in turn, hampered the growth of NEPC. We then identified the protein syndecan-1 (SDC1) as the NEPC-specific TLR2/TLR4 ligand that triggered this pathway. Interrogating published single-cell RNA-sequencing data, we validated this mechanism in a different mouse model. Translational relevance of the results was provided by in silico analyses of available human NEPC datasets and by immunofluorescence on patient-derived adenocarcinoma and NEPC lesions. Overall, our results show that MCs actively inhibit NEPC, paving the way for innovative MC-based therapies for this fatal tumor. We also highlight SDC1 as a potential biomarker for incipient NEPC.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Background EZH2 promotes aggressive-variant prostate cancer (AVPC) progression via histone H3-Lysine-27 tri-methylation (H3K27me3). We hypothesize that epigenetic reprogramming via EZH2 inhibitors (EZH2i) improves the efficacy of chemotherapy in AVPC. Methods We studied the expression of EZH2 in clinical prostate cancer cohorts (bioinformatics). We determined the effect of EZH2i on both cellular- and cell-free-H3K27me3 levels. We measured effects of carboplatin with/without EZH2i on AVPC cell viability (IC 50 ). We studied how EZH2i modulate gene expression (RNA Seq). Results EZH2 was significantly up-regulated in AVPC vs other prostate cancer types. EZH2i reduced both cellular and cell free-H3K27me3 levels. EZH2i significantly reduced carboplatin IC 50 . EZH2i reduced the expression of DNA repair and increased the expression of pro-apoptotic genes. Article Highlights Polycomb-mediated gene silencing promotes prostate cancer progression Aggressive-variant prostate cancers (AVPCs) are characterized by increased activity of the Polycomb-Repressive Complex 2 (PRC2) Here we show that PRC2 inhibitors are scarcely effective as monotherapy in ACPC cells However the combination of PRC2 inhibitors and carboplatin is highly synergistic RNA Seq studies revealed that PRC2 inhibitors enhance carboplatin activity by modulating several key pathways, including DNA repair and apoptosis.
Year:
2024
Supplementary Figure S6. Quantification of western blot. A. Quantification of western blot reported in Fig. 3G. Western blots were validated twice. All histograms depict mean ± SD of biological replicates (represented by dots). One-way ANOVA followed by Tukey’s multiple comparison test was used for the analysis of significance between samples. P -values are reported as: *, P P P P P -value is not indicated, the comparison between groups is not statistically significant.
Year:
2024
Supplementary Figure S3. Toluidine blue for detection of MCs in mice. A. MC count reported as number of MCs/tumor area (cm2) in tumor samples from TRAMP mice with prostate intraepithelial neoplasia or adenocarcinoma (PIN/ADENO, n = 12), or TRAMP mice with NEPC ( n = 3), as well as in prostatectomies from untreated patients with Gleason Score 7 ( n = 10), Gleason Score 8 ( n =10), or showing evidence of NEPC ( n = 4). The histogram depict mean ± SD of biological replicates (represented by dots). B. Upper panels: representative images of toluidine blue staining in TRAMP, KitWsh-TRAMP, and OPN-/-TRAMP mice, or in KitWsh-TRAMP mice reconstituted with WT, OPN-/- or TNFa-/- MCs. Lower panels: representative images of toluidine blue staining in a prostate of a patient with adenocarcinoma. Scale bars indicate magnifications.
Year:
2024
Supplementary Figure S3. Toluidine blue for detection of MCs in mice. A. MC count reported as number of MCs/tumor area (cm2) in tumor samples from TRAMP mice with prostate intraepithelial neoplasia or adenocarcinoma (PIN/ADENO, n = 12), or TRAMP mice with NEPC ( n = 3), as well as in prostatectomies from untreated patients with Gleason Score 7 ( n = 10), Gleason Score 8 ( n =10), or showing evidence of NEPC ( n = 4). The histogram depict mean ± SD of biological replicates (represented by dots). B. Upper panels: representative images of toluidine blue staining in TRAMP, KitWsh-TRAMP, and OPN-/-TRAMP mice, or in KitWsh-TRAMP mice reconstituted with WT, OPN-/- or TNFa-/- MCs. Lower panels: representative images of toluidine blue staining in a prostate of a patient with adenocarcinoma. Scale bars indicate magnifications.
Year:
2024
Supplementary Figure S2. OPN evaluation in bone marrow-derived MCs. A. Separate channels of immunofluorescence for DAPI (cyan), OPN (red) and WGA (blue) of WT and OPN-/- MCs showed in Fig. 1A B. Representative images of 3 different biological replicates of immunofluorescence for DAPI (cyan), OPN (red) and WGA (blue), in WT and OPN-/- MCs. These pictures were used for the quantification reported in Fig. 1B.
Year:
2024
Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer that emerges as tumors become resistant to hormone therapies or, rarely, arises de novo in treatment-naïve patients. The urgent need for effective therapies against NEPC is hampered by the limited knowledge of the biology governing this lethal disease. Based on our prior observations in the transgenic adenocarcinoma of the mouse prostate (TRAMP) spontaneous prostate cancer model, in which the genetic depletion of either mast cells (MC) or the matricellular protein osteopontin (OPN) increases NEPC frequency, we tested the hypothesis that MCs can restrain NEPC through OPN production, using in vitro co-cultures between murine or human tumor cell lines and MCs, and in vivo experiments. We unveiled a role for the intracellular isoform of OPN, so far neglected compared with the secreted isoform. Mechanistically, we unraveled that the intracellular isoform of OPN promotes TNFα production in MCs via the TLR2/TLR4-MyD88 axis, specifically triggered by the encounter with NEPC cells. We found that MC-derived TNFα, in turn, hampered the growth of NEPC. We then identified the protein syndecan-1 (SDC1) as the NEPC-specific TLR2/TLR4 ligand that triggered this pathway. Interrogating published single-cell RNA-sequencing data, we validated this mechanism in a different mouse model. Translational relevance of the results was provided by in silico analyses of available human NEPC datasets and by immunofluorescence on patient-derived adenocarcinoma and NEPC lesions. Overall, our results show that MCs actively inhibit NEPC, paving the way for innovative MC-based therapies for this fatal tumor. We also highlight SDC1 as a potential biomarker for incipient NEPC.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (14)
Benedetto Grimaldi
Senior Researcher
Istituto Italiano di Tecnologia
Shusuke Akamatsu
Professor
Nagoya University Hospital
Daniele Lecis
Fondazione IRCCS Istituto Nazionale dei Tumori
Claudio Tripodo
-
Milena Perrone
Fondazione IRCCS Istituto Nazionale dei Tumori
Elda Tagliabue
Head of Molecular Targeting Unit
Fondazione IRCCS Istituto Nazionale dei Tumori
Sabina Sangaletti
Fondazione IRCCS Istituto Nazionale dei Tumori
Carlo Pucillo
Full Professor
University of Udine
Sushila Rigas
Open University
Mario Paolo Colombo
Head of Department
Fondazione IRCCS Istituto Nazionale dei Tumori
Francesco Crea
Professor (Chair) of Cancer Pharmacology
Open University
Roberta Sulsenti
Open University
Claudia Chiodoni
Senior Staff scientist
Fondazione IRCCS Istituto Nazionale dei Tumori
Valeria Cancila
Assistant Professor
University of Palermo
Make your next move.
Prepare your application
Review drafts before you send them.